PT1401442E - S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas) - Google Patents

S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas)

Info

Publication number
PT1401442E
PT1401442E PT02776528T PT02776528T PT1401442E PT 1401442 E PT1401442 E PT 1401442E PT 02776528 T PT02776528 T PT 02776528T PT 02776528 T PT02776528 T PT 02776528T PT 1401442 E PT1401442 E PT 1401442E
Authority
PT
Portugal
Prior art keywords
omeprazolo
esomeprazole
cyclodextrins
inclusion complex
cyclodextrin
Prior art date
Application number
PT02776528T
Other languages
English (en)
Inventor
Hamied Yusuf Khwaja
Rao Dharmaraj Ramachandra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of PT1401442E publication Critical patent/PT1401442E/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT02776528T 2001-06-06 2002-06-06 S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas) PT1401442E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex

Publications (1)

Publication Number Publication Date
PT1401442E true PT1401442E (pt) 2005-02-28

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02776528T PT1401442E (pt) 2001-06-06 2002-06-06 S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas)

Country Status (18)

Country Link
US (1) US20040147481A1 (pt)
EP (1) EP1401442B1 (pt)
JP (1) JP2004536810A (pt)
AT (1) ATE282412T1 (pt)
AU (1) AU2002344386B2 (pt)
CA (1) CA2449769C (pt)
DE (1) DE60201995T2 (pt)
ES (1) ES2232780T3 (pt)
GB (1) GB2376231A (pt)
HK (1) HK1064602A1 (pt)
LT (1) LT5182B (pt)
LV (1) LV13154B (pt)
NZ (1) NZ529956A (pt)
PL (1) PL366940A1 (pt)
PT (1) PT1401442E (pt)
RU (1) RU2313343C2 (pt)
WO (1) WO2002098423A1 (pt)
ZA (1) ZA200309841B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
ES2325336T3 (es) * 2005-12-28 2009-09-01 Union Quimico-Farmaceutica, S.A. Procedimiento para la preparacion del enantiomero (s) de omeprazol.
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 s-오메프라졸 함유 포접 복합체 및이의 제조방법
DK2106397T3 (da) 2007-09-25 2012-01-30 Hetero Drugs Ltd Fremgangsmåde til fremstilling af enantiomer-ren esomeprazol
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (pt) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CZ291842B6 (cs) * 1997-03-13 2003-06-18 Hexal Ag Farmaceutická formulace
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
JP4312405B2 (ja) * 1999-08-26 2009-08-12 エイエイアイファーマ・インコーポレイテッド アルコキシ置換ベンズイミダゾール化合物、それを含む医薬製剤物、およびそれを使用する方法
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
CA2449769C (en) 2010-12-14
US20040147481A1 (en) 2004-07-29
NZ529956A (en) 2005-07-29
ZA200309841B (en) 2005-03-14
JP2004536810A (ja) 2004-12-09
RU2003137221A (ru) 2005-06-10
LT5182B (lt) 2004-12-27
PL366940A1 (en) 2005-02-07
ES2232780T3 (es) 2005-06-01
RU2313343C2 (ru) 2007-12-27
GB0113792D0 (en) 2001-07-25
HK1064602A1 (en) 2005-02-04
EP1401442B1 (en) 2004-11-17
LT2003100A (en) 2004-09-27
GB2376231A (en) 2002-12-11
DE60201995T2 (de) 2005-11-24
EP1401442A1 (en) 2004-03-31
ATE282412T1 (de) 2004-12-15
DE60201995D1 (de) 2004-12-23
AU2002344386B2 (en) 2006-11-30
WO2002098423A1 (en) 2002-12-12
CA2449769A1 (en) 2002-12-12
LV13154B (en) 2004-07-20

Similar Documents

Publication Publication Date Title
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
CL2008002673A1 (es) Procedimiento se preparacion de citalopram que comprende hacer reaccionar un compuesto derivado de benzofurano con un agente eshidratante y una sulfonamida (div. sol. 2003-01).
ATE485835T1 (de) Antikörper enthaltende pharmazeutische lösungen
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
AR033096A1 (es) Acomposicion antifungal con aumentada biodisponibilidad
PT1401442E (pt) S-omeprazolo (complexo de inclusao de esomeprazolo com ciclodextrinas)
ECSP066662A (es) Preparación farmacéutica que comprende un anticuerpo contra el receptor egf
ECSP045104A (es) Ligandos de los receptores de los cannabinoides
DE60035356D1 (de) Faktor ix/faktor ixa aktivierende antikörper
MXPA03011006A (es) Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
WO2003057135A3 (en) Aqueous compositions containing metronidazole
NO20034660D0 (no) Spiropyrazolforbindelser
EE05402B1 (et) Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks
PE20070378A1 (es) FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
DE60321484D1 (de) Aktivitätsüberwachung
AR041639A1 (es) Metodo para la sintesis de un compuesto de bencimidazol
NO20041671L (no) Anthelmintic composition
TR200402322T4 (tr) Triptaz inhibitörler
DK1244614T3 (da) Tryptase-inhibitorer
DE60334929D1 (de) Algainassb-ätzung
EA200400382A1 (ru) Применение специфической дозы фондапаринукса натрия для лечения окс
PT1380208E (pt) Agente desinfectante com actividade antiparasitica
ATE340577T1 (de) Mittel gegen posttraumatische stresszustände